诱导多能干细胞
类有机物
药物代谢
药品
药物发现
生物
细胞色素P450
干细胞
药理学
药物开发
细胞生物学
新陈代谢
生物信息学
生物化学
胚胎干细胞
基因
作者
Hyemin Kim,Ilkyun Im,Jang Su Jeon,Eun‐Hye Kang,Hyang‐Ae Lee,Seongyea Jo,Ji‐Woo Kim,Dong–Hun Woo,Young Jae Choi,Hyo Jin Kim,Ji‐Seok Han,Byoung‐Seok Lee,Jong‐Hoon Kim,Sang Kyum Kim,Han‐Jin Park
出处
期刊:Biomaterials
[Elsevier]
日期:2022-05-16
卷期号:286: 121575-121575
被引量:35
标识
DOI:10.1016/j.biomaterials.2022.121575
摘要
Human in vitro hepatic models that faithfully recapitulate liver function are essential for successful basic and translational research. A limitation of current in vitro models, which are extensively used for drug discovery and toxicity testing, is the loss of drug metabolic function due to the low expression and activity of cytochrome P450 (CYP450) enzymes. Here, we aimed to generate human pluripotent stem cell-derived hepatic organoids (hHOs) with a high drug metabolic ability. We established a two-step protocol to produce hHOs from human pluripotent stem cells for long-term expansion and drug testing. Fully differentiated hHOs had multicellular composition and exhibited cellular polarity and hepatobiliary structures. They also displayed remarkable CYP450 activity and recapitulated the metabolic clearance, CYP450-mediated drug toxicity, and metabolism. Furthermore, hHOs successfully modeled Wilson's disease in terms of Cu metabolism, drug responses, and diagnostic marker expression and secretion. In conclusion, hHOs exhibit high capacity for drug testing and disease modeling. Hence, this hepatic model system provides an advanced tool for studying hepatic drug metabolism and diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI